APLS Working Capital Per Revenue	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Working Capital Change	-6.69 %	17.63 %	6.27 %	-2.9 %	-26.91 %
Y / Y Revenue Change	-3.21 %	45.19 %	78.29 %	110.26 %	284.26 %
Working Capital Per Revenue	0.81	0.82	0.86	0.96	1.17
Working Capital Per Revenue Ranking	# 1833	# 2563	# 2542	# 2607	# 2739
Seq. Working Capital Change	-8.84 %	-6.04 %	-6.83 %	16.92 %	14.92 %
Seq. Revenue Change	-21.52 %	7.97 %	-1.43 %	15.88 %	17.73 %

New: More APLS's historic Working Capital Per Revenue Ratios >>

Financial strength information by company within the Major Pharmaceutical Preparations industry >> Back to APLS Financial Strength Comparisons >> See APLS Balance Sheets

Comment on APLS's Working Capital Per Revenue in the first quarter 2025

Apellis Pharmaceuticals Inc 's Working Capital Per Revenue in the Q1 2025 sequentially fell to 0.81 below the company average. Due to decrease of revenue year on year in the first quarter 2025 by -3.21%.

Within Healthcare sector 32 other companies have achieved lower Working Capital Per Revenue during the Q1 2025. While Apellis Pharmaceuticals Inc Working Capital Per Revenue overall ranking has impoved so far in the Q1 2025 to 1833, from total ranking in the fourth quarter 2024 at 2563.

Working Capital Per Revenue Ranking
Within:	No.
Industry	# 10
Sector	# 33
S&P 500	# 1833

Working Capital Per Revenue Statistics
High	Average	Low
10.21	4.01	0.8
(Dec 31 2022)		(Mar 31 2025)

Financial Statements
Apellis Pharmaceuticals Inc 's Working Capital	$ 556 Millions	Visit APLS's Balance sheet
Apellis Pharmaceuticals Inc 's Revenues	$ 167 Millions	Visit APLS's Income Statement
Where are APLS's Sales coming from?		Visit APLS's Sales by Geography

Companies with similar Average Working Capital Per Revenue for 12 months ending Mar 31 2025, within Healthcare Sector	Working Capital Per Revenue
Ginkgo Bioworks Holdings Inc	2.22
Xenetic Biosciences Inc	2.22
Humacyte Inc	2.10
Outset Medical Inc	2.06
Amarin Corp Plcuk	2.04
Cvrx inc	2.04
Moderna Inc	2.03
Butterfly Network Inc	2.00
Oncocyte Corporation	1.99
Arvinas Inc	1.98
Maravai Lifesciences Holdings Inc	1.98
Rhythm Pharmaceuticals inc	1.94
Krystal Biotech Inc	1.92
Orasure Technologies Inc	1.92
Scpharmaceuticals Inc	1.92
Assembly Biosciences Inc	1.90
Tenon Medical Inc	1.89
Omniab Inc	1.87
Invivyd Inc	1.87
Rxsight Inc	1.79
Pacific Health Care Organization Inc	1.77
Iovance Biotherapeutics inc	1.76
Arcturus Therapeutics Holdings Inc	1.72
Meiragtx Holdings Plc	1.69
Theravance Biopharma inc	1.67
Schrodinger Inc	1.67
Vanda Pharmaceuticals Inc	1.65
Cytek Biosciences Inc	1.65
Personalis Inc	1.64
Sight Sciences Inc	1.60

Date modified: 2025-05-09T06:32:06+00:00

Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com